Evommune (EVMN) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Evommune reported total assets of $224.95M and total liabilities of $19.38M. Shareholders' equity was $205.57M. Total debt stood at $2.06M against $149.20M in cash and short-term investments, a net cash position of $147.14M. That puts debt-to-equity at 0.01.

Evommune Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Evommune, Inc. (EVMN) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023
Period ending	Dec 2025	Dec 2024	Dec 2023
Current Assets
Cash and Cash Equivalents	44.06	16.25	29.02
Short-Term Investments	105.14	55.79	50.06
Cash & Short-Term Investments	149.20	72.04	79.08
Accounts Receivable	0.00	0.00	0.00
Inventory	0.00	0.00	0.00
Other Current Assets	4.28	1.95	0.95
Total Current Assets	153.48	73.99	80.03
Non-Current Assets
Property, Plant & Equipment (Net)	2.46	1.80	1.97
Long-Term Investments	67.49	0.21	0.21
Other Non-Current Assets	1.52	0.06	0.04
Total Non-Current Assets	71.47	2.07	2.22
Total Assets	224.95	76.06	82.25
Current Liabilities
Accounts Payable	7.76	8.26	1.76
Short-Term Debt	0.59	1.02	0.77
Accrued Liabilities	9.55	6.73	4.03
Deferred Revenue	0.00	3.00	0.00
Other Current Liabilities	0.36	15.70	4.33
Total Current Liabilities	17.91	27.98	6.86
Non-Current Liabilities
Long-Term Debt	1.47	192.30	149.86
Other Non-Current Liabilities	0.18	0.02	0.25
Total Non-Current Liabilities	1.47	192.31	153.11
Total Liabilities	19.38	220.29	159.96
Stockholders' Equity
Common Stock	0.00	0.00	0.00
Retained Earnings	-221.09	-152.22	-83.91
Additional Paid-in Capital	426.65	7.98	6.20
Shares Outstanding	31.52	-	-
Total Stockholders' Equity	205.57	-144.24	-77.71
Total Liabilities & Equity	224.95	76.06	82.25

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Evommune Balance Sheet

How much debt does Evommune have?

Evommune had total debt of $2.06M as of Dec 31, 2025, against $149.20M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was $193.31M a year earlier.

What are Evommune's total assets?

Evommune reported total assets of $224.95M as of Dec 31, 2025, up 195.8% from $76.06M a year earlier. Total liabilities were $19.38M.

What is Evommune's shareholders' equity?

Evommune's shareholders' equity was $205.57M as of Dec 31, 2025, or about $6.52 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition